A limitation of our clinical study is the absence of comparator groups, specifically those receiving CD19 CAR-T cell infusion, CD22 CAR-T cell infusion, or a combination of CD19/CD22 CAR-T cell infusions, which would elucidate therapeutic efficacies in r/r B-ALL patients. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.